Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
We report a case of bedaquiline and delamanid resistance in a 55-year-old woman in South Africa with extensively drug-resistant tuberculosis and known HIV.PMID:37081529 | DOI:10.3201/eid2905.221716 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - April 25, 2023 Category: Infectious Diseases Authors: James Millard Stephanie Rimmer Camus Nimmo Max O'Donnell Source Type: research
Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
We report a case of bedaquiline and delamanid resistance in a 55-year-old woman in South Africa with extensively drug-resistant tuberculosis and known HIV.PMID:37081529 | DOI:10.3201/eid2905.221716 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - April 23, 2023 Category: Infectious Diseases Authors: James Millard Stephanie Rimmer Camus Nimmo Max O'Donnell Source Type: research
Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
We report a case of bedaquiline and delamanid resistance in a 55-year-old woman in South Africa with extensively drug-resistant tuberculosis and known HIV.PMID:37081529 | DOI:10.3201/eid2905.221716 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - April 22, 2023 Category: Infectious Diseases Authors: James Millard Stephanie Rimmer Camus Nimmo Max O'Donnell Source Type: research
Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
J. Millard et al. (Source: Emerging Infectious Diseases Journal)
Source: Emerging Infectious Diseases Journal - April 14, 2023 Category: Infectious Diseases Source Type: research
"Weighting" the Evidence: How Much Bedaquiline Is Enough?
Am J Respir Crit Care Med. 2023 Apr 12. doi: 10.1164/rccm.202303-0373ED. Online ahead of print.NO ABSTRACTPMID:37043826 | DOI:10.1164/rccm.202303-0373ED (Source: American Journal of Respiratory and Critical Care Medicine)
Source: American Journal of Respiratory and Critical Care Medicine - April 12, 2023 Category: Respiratory Medicine Authors: James C M Brust Source Type: research
"Weighting" the Evidence: How Much Bedaquiline Is Enough?
Am J Respir Crit Care Med. 2023 Apr 12. doi: 10.1164/rccm.202303-0373ED. Online ahead of print.NO ABSTRACTPMID:37043826 | DOI:10.1164/rccm.202303-0373ED (Source: Respiratory Care)
Source: Respiratory Care - April 12, 2023 Category: Respiratory Medicine Authors: James C M Brust Source Type: research
"Weighting" the Evidence: How Much Bedaquiline Is Enough?
Am J Respir Crit Care Med. 2023 Apr 12. doi: 10.1164/rccm.202303-0373ED. Online ahead of print.NO ABSTRACTPMID:37043826 | DOI:10.1164/rccm.202303-0373ED (Source: Am J Respir Crit Car...)
Source: Am J Respir Crit Car... - April 12, 2023 Category: Intensive Care Authors: James C M Brust Source Type: research
Design, synthesis, biochemical and in silico characterization of novel naphthalene-thiourea conjugates as potential and selective inhibitors of alkaline phosphatase
AbstractNaphthalene ring is present in a number of FDA-approved, commercially available medications, including naphyrone, terbinafine, propranolol, naproxen, duloxetine, lasofoxetine, and bedaquiline. By reacting newly obtained 1-naphthoyl isothiocyanate with properly modified anilines, a library of ten novel naphthalene-thiourea conjugates (5a –5j) were produced with good to exceptional yields and high purity. The newly synthesized compounds were observed for their potential to inhibit alkaline phosphatase (ALP) and scavenge free radicals. All of the investigated compounds displayed a more powerful inhibitory profile th...
Source: Medicinal Chemistry Research - April 10, 2023 Category: Chemistry Source Type: research
QTc prolongation with bedaquiline treatment for drug-resistant pulmonary TB in a programmatic setting
(Source: International Journal of Tuberculosis and Lung Disease)
Source: International Journal of Tuberculosis and Lung Disease - April 7, 2023 Category: Respiratory Medicine Authors: Sachdeva, K. S. Bhatnagar, A. K. Bhaskar, A. Singla, N. Sridhar, R. Ramraj, B. Athawale, A. Solanki, R. Baruah, S. R. Patel, Y. Ramachandran, R. Padmapriyadarsini, C. Tags: FORUM-Letter Source Type: research
Bedaquiline exposure in people with drug-resistant TB treated for diabetes: analysis of two phase 2 trials
(Source: International Journal of Tuberculosis and Lung Disease)
Source: International Journal of Tuberculosis and Lung Disease - April 7, 2023 Category: Respiratory Medicine Authors: Bolhuis, M. S. Akkerman, O. W. Sturkenboom, M. G. G. van Boven, J. F. M. Alffenaar, J-W. C. Stevens, J. Tags: FORUM-Letter Source Type: research
End of the Bedaquiline patent – a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income countries.
When Johnson& Johnson (J&J) developed the new tuberculosis (TB) drug bedaquiline (Sirturo),[1] it was one the few new drugs to have been conditionally approved by the United States Food and Drug Administration (FDA) in 2012 for treatment of multi-drug resistant tuberculosis (MDR-TB). It offered renewed hope to patients providing a unique opportunity to radically transform management of MDR-TB to shorter, easier-to-administer, and more patient-tolerable treatment regimens.[2] Evaluation in clinical trials over the ensuing seven years showed that bedaquiline was a game-changer, demonstrating substantial improved treatment ou...
Source: International Journal of Infectious Diseases - April 6, 2023 Category: Infectious Diseases Authors: Eskild Petersen, David S Hui, Jean B Nachega, Francine Ntoumi, Delia Goletti, Eleni Aklillu, Avinash Sharma, Thomas Nyirenda, Dorothy Yeboah-Manu, Giovanni Satta, Christopher da Costa, Esam I Azhar, Moses Bockarie, Seif Al-Abri, Timothy D McHugh, Alfonso Source Type: research
Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
Conclusion: We established a population PK model for bedaquiline in patients with MDR-TB in China. Based on the thresholds and MIC distribution derived in a clinical study, the recommended dosage of bedaquiline is sufficient for the treatment of MDR-TB. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - March 27, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models
ConclusionPBTZ169 appears to be a candidate for treating four common NTM infections. Pretomanid was more active against M. abscessus, M. chelonae and M. fortuitum than against M. avium. (Source: Frontiers in cellular and infection microbiology)
Source: Frontiers in cellular and infection microbiology - March 22, 2023 Category: Microbiology Source Type: research
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
Antimicrob Agents Chemother. 2023 Mar 15:e0003523. doi: 10.1128/aac.00035-23. Online ahead of print.ABSTRACTA regimen comprised of bedaquiline (BDQ, or B), pretomanid, and linezolid (BPaL) is the first oral 6-month regimen approved by the U.S. Food and Drug Administration and recommended by the World Health Organization for the treatment of extensively drug-resistant tuberculosis. We used a well-established BALB/c mouse model of tuberculosis to evaluate the treatment-shortening potential of replacing bedaquiline with either of two new, more potent diarylquinolines, TBAJ-587 and TBAJ-876, in early clinical trials. We also e...
Source: Antimicrobial Agents and Chemotherapy - March 15, 2023 Category: Microbiology Authors: Si-Yang Li Paul J Converse Fabrice Betoudji Jin Lee Khisimuzi Mdluli Anna Upton Nader Fotouhi Eric L Nuermberger Source Type: research
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
Antimicrob Agents Chemother. 2023 Mar 15:e0003523. doi: 10.1128/aac.00035-23. Online ahead of print.ABSTRACTA regimen comprised of bedaquiline (BDQ, or B), pretomanid, and linezolid (BPaL) is the first oral 6-month regimen approved by the U.S. Food and Drug Administration and recommended by the World Health Organization for the treatment of extensively drug-resistant tuberculosis. We used a well-established BALB/c mouse model of tuberculosis to evaluate the treatment-shortening potential of replacing bedaquiline with either of two new, more potent diarylquinolines, TBAJ-587 and TBAJ-876, in early clinical trials. We also e...
Source: Antimicrobial Agents and Chemotherapy - March 15, 2023 Category: Microbiology Authors: Si-Yang Li Paul J Converse Fabrice Betoudji Jin Lee Khisimuzi Mdluli Anna Upton Nader Fotouhi Eric L Nuermberger Source Type: research
